105
Participants
Start Date
December 21, 2020
Primary Completion Date
December 31, 2026
Study Completion Date
December 31, 2026
Durvalumab
Induction phase: Durvalumab (1500 mg once every 3 weeks) for 4-6 cycles in combination with standard of care (Radiochemotherapy) Maintenance phase: Durvalumab (1500 mg once every 4 weeks) until PD or unacceptable toxicities.
standard of care
"Radiochemotherapy: Cisplatin (75 mg/m² (BSA) D1#) or alternatively Carboplatin (AUC 5 D1) and Etoposide (100 mg/m² (BSA) D1-3) once every 3 weeks for 4-6 cycles and concomitant Radiotherapy (60±6 Gy, 1.8-2 Gy/d or 45±1.5 Gy (1.5 Gy per fraction twice daily, with 4 hours or more between fractions) with start at latest at beginning of cycle 3, ideally during cycle 1) followed by prophylactic cranial irradiation (PCI, if clinically indicated and according to local standard at any time after completion of radio-chemotherapy))~A simultaneous administration of platinum-based chemotherapy (preferred Cisplatin) and radiotherapy for at least 2 cycles should be performed."
Klinikum Ernst von Bergmann, Potsdam
Universitätsmedizin Rostock, Rostock
Asklepios Klinikum Hamburg, Hamburg
Johannes Wesling Klinikum Minden, Minden
Klinikum Kassel GmbH-Klinik für Onkologie und Hämatologie, Kassel
Universitätsklinikum Gießen Marburg, Giessen
KEM GmbH, Essen
Universitätsklinikum Essen, Essen
Lungenklinik Köln-Merheim, Cologne
Universitätsklinikum Aachen, Aachen
Lungenklinik Hemer, Hemer
Sana-Klinikum Offenbach, Offenbach
Klinik Löwenstein gGmbH, Löwenstein
Asklepios Fachkliniken Muenchen Gauting, München Gauting
Klinikverbund Allgäu gGmbH, Immenstadt im Allgäu
Helios Kliniken Erfurt, Erfurt
Collaborators (1)
AstraZeneca
INDUSTRY
Michael Hopp
OTHER